The recent update of the American Urological Association 2026 guidelines and the evidence presented at the EAU 2026 confirm a trend that may mark a clear boundary: the transition from a “linear” diagnostic approach to an advanced model of algorithm-assisted decision-making.

This paradigm shift does not aim to replace the clinician’s judgment, but rather to enhance it with a technological “second look” capable of processing today’s growing data complexity. The approach is evolving from sequential steps to an integrated analysis, where artificial intelligence acts as an ally to make the diagnostic pathway more robust, transparent, and personalized.

A signal of transition

It is within this highly rigorous framework that Artificial Intelligence begins to emerge. Although it is not yet part of operational clinical recommendations — which remain firmly grounded in established evidence — the guidelines explicitly identify it among the “Future Directions”.

This reference, albeit cautious, is meaningful: AI is recognized as having the potential to address key unresolved challenges in prostate diagnostics, such as variability in imaging interpretation and the need to integrate increasingly large and complex clinical datasets.

Health Triage’s vision: PROSTATE V-Bio

It is precisely within this “Future Directions” framework that the development of PROSTATE V-Bio takes place.

Designed to transform biparametric MRI into a true “virtual biopsy”, the system estimates tumor aggressiveness by classifying lesions according to the Gleason Grade Group standard.

The goal is to provide urologists with an additional tool to support more informed decision-making regarding patient management — particularly when deciding whether to proceed with a tissue biopsy.

Ultimately, the aim is to reduce unnecessary invasive biopsies, with a strong focus on improving patients’ quality of life.

Limitations and scientific rigor

Despite its potential, we are fully aware that this transition is still ongoing.

Our technology is currently under development, and we believe that dataset quality, transparency, and external validation are non-negotiable requirements.